CTLA4 and neoplasm: Studies have found that in the TME of breast cancer patients, after Tregs bind to APCs via CTLA4, the expression of MHCII molecules on the APC surface decreases by about 30%, significantly reducing their ability to present tumor antigens to effector T cells (206, 207).